The current stock price of KMDA is 7.06 USD. In the past month the price increased by 2.02%. In the past year, price increased by 9.46%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
KAMADA LTD
2 Holtzman St., Science Park
Rehovot 7670402 IL
CEO: Amir London
Employees: 374
Phone: 97289406472
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
The current stock price of KMDA is 7.06 USD. The price decreased by -0.7% in the last trading session.
KAMADA LTD (KMDA) has a dividend yield of 2.83%. The yearly dividend amount is currently 0.
KMDA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
KMDA stock is listed on the Nasdaq exchange.
KAMADA LTD (KMDA) has a market capitalization of 407.22M USD. This makes KMDA a Small Cap stock.
You can find the ownership structure of KAMADA LTD (KMDA) on the Ownership tab.
ChartMill assigns a technical rating of 5 / 10 to KMDA. When comparing the yearly performance of all stocks, KMDA turns out to be only a medium performer in the overall market: it outperformed 65.87% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to KMDA. While KMDA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months KMDA reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 28.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.7% | ||
| ROA | 5.42% | ||
| ROE | 7.72% | ||
| Debt/Equity | 0.04 |
9 analysts have analysed KMDA and the average price target is 13.26 USD. This implies a price increase of 87.82% is expected in the next year compared to the current price of 7.06.
For the next year, analysts expect an EPS growth of 44.17% and a revenue growth 12.37% for KMDA